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Background: Radiotherapy (RT) plays an important role in the multidisciplinary management
of Ewing’s Sarcoma (ES), especially in unresectable cases.
Aim: Assessment of efﬁcacy of RT in terms of local control in pediatric patients with primary
ES of bone.
Materials and methods: Thirty-six patients younger than 17 years old with ES treated with
combined RT and chemotherapy with (N=14) or without (N=22) prior surgery from 1981 to
2008 were retrospectively reviewed. Since 1995, they were all treated according to the Span-
ish Society of Pediatric Oncology protocol (55.5% cases). Those patients received vincristine,
ifosfamide, doxorubicin and etoposide. The TNM classiﬁcation was as follows: 17 T1, 18 T2
and 1 T3; 36 N0; 29 M0, 5 M1a and 2 M1b. Analysis was stratiﬁed by treatment: deﬁnitive RT
or pre/postoperative RT.
Results: The 36 patients (21 male; 15 female) had a median age of 10 years (range 2–17
years). Median follow-up of living patients was 105 months. The 2-year local control (LC)
rate for all patients was 88%. Five-year LC rates for patients treated with deﬁnitive and
pre/postoperative RT were 91% and 86%, respectively. Two-year overall survival and disease-
free survival rates for all patients were 68% and 66%, respectively. Low phosphatase alkaline
levels and local and distant recurrences were signiﬁcantly predictive of worse prognosis
(P=0.021, P=0.011, P=0.007, respectively).Conclusion:Radiotherapywithandwithout surgery is ahighly effective local treatment option
in the multidisciplinary management of ES in pediatric patients.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
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Table 1 – Ewing’s Sarcoma treatment protocols.
Protocol N (%) Date
T9 10 (27.8%) 1981–1990
POG/P6 2/4 (5.6/11.1%) 1991–1994104 reports of practical oncology an
1. Background
The Ewing family of tumors is the second most common
primary osseous malignancy in childhood and adolescence.1
Classically, these tumors originate in the bone, although they
can also occur in soft tissue and be the result of a transloca-
tion between chromosomes 11 and 22.2 The annual incidence
of Ewing Sarcoma (ES) in the United States is 2.93 per mil-
lion children.3 Approximately 50% of patients with Ewing
tumors are aged 10–20 years. Another 20–30% of cases are
diagnosed in the ﬁrst decade. Although cases continue to be
diagnosed throughout the third decade and beyond, the inci-
dence is much lower. Since 1970, the survival of patients with
ES has increased substantially.4 These tumors are aggressive,
and multimodality therapy is always required. The selec-
tion of appropriate systemic therapy has been guided by
both prospective and randomized studies5–9 integrating a
multiagent systemic therapy into induction and adjuvant
therapeutic approaches. No randomized study has addressed
the selection of local tumor control modalities for patients
with ES, but during the past 20 years, local management has
generally evolved fromdeﬁnitive radiotherapy (RT) to limb sal-
vage surgical approaches.5,6,9,10 The reason for this evolution
is multifactorial and includes the suggestion of a greater local
control with surgery, improvements in surgical techniques,
and a concern about possible secondarymalignancies and late
effects caused by RT.11–16
2. Aim
The objective of the present study is to evaluate the clin-
ical characteristics and local control of children patients
treated with deﬁnitive RT for unresectable ES or with
pre/postoperative RT for patients with high risk disease (axial
primaries or large residual tumors after induction chemother-
apy). Another goal of this study is to ﬁnd whether there is a
signiﬁcant difference in terms of local control between these
two groups. Finally, our objective for this retrospective study
is to evaluate other survival outcomes and prognostic factors.
3. Materials and methods
3.1. Patients
The institutional review board approved a retrospective chart
review which was conducted for all pediatric (≤17 years old)
patients diagnosed with ES between 1981 and 2008 at our
institution. We identiﬁed 79 patients; 2 were excluded for
the following reasons: disease progression before planned
RT (N=1) and wrong diagnosis (N=1). Of the remaining
77 patients, 41 (53%) were treated with chemotherapy and
deﬁnitive surgery; 14 (18%) were treated with chemotherapy,
deﬁnitive surgery (wide local or marginal excision), and RT;
and 22 (29%) were treated with chemotherapy and deﬁnitive
RT. Therefore, the 36 patients, who underwent deﬁnitive or
pre/postoperative RT for local management, were the subject
of this report. The patients in this group were treated on sev-
eral institutional or national prospective studies of ES thatSpanish Society of
Pediatric Oncology
20 (55.5%) 1995–2008
Abbreviations: POG=Pediatric Oncology Group.
included different protocol guidelines. The TNM classiﬁcation
according to the American Joint Committee on Cancer 2002
staging system for bone cancer was as follows: 17 T1, 18 T2
and 1 T3; 36 N0; 29 M0, 5 M1a and 2 M1b.
3.2. Approach to management
Our practice has largely reﬂected the evolving cooperative
group standards for RT. Since 1995, they were all treated
according to the Spanish Society of Pediatric Oncology (SEOP)
protocol for ES. This protocol divided patients into ﬁve cat-
egories: (1) resectable location and no distant metastasis, (2)
unresectable location and no distant metastasis, (3) resectable
location and lung metastasis, (4) unresectable location and
lung metastasis, and (5) multicentric tumor or other distant
metastasis. The standard treatment scheme was as follows:
induction chemotherapy, surgery (resectable cases) with or
without adjuvant radiotherapy, consolidation chemotherapy
(concurrent with postoperative radiotherapy if indicated),
bone marrow transplant, when indicated, and deﬁnitive radi-
ation therapy for unresectable cases.
3.3. Surgery
Fourteen patients (66.2%) were treated with surgery. Four
(28.6% of patients treated with surgery) had positive margins
and ten (71.4%) poor histological tumor response after induc-
tion chemotherapy (>10% viable tumor cells). Limb-salvage
surgery was preferred over amputation.
3.4. Systemic therapy
The ﬁrst protocol used at our institution (T-9) consisted of
ﬁve cycles of Actinomycin D, doxorubicin, cyclophosphamide,
vincristine, methotrexate, and bleomycin administered over
a forty-ﬁve-week period.17 More recently, pediatric patients
have been treated according to the Memorial Sloan-Kettering
Cancer Center P6 protocol,18 which includes cycles of
cyclophosphamide/doxorubicin/vincristine and cycles of ifos-
famide/etoposide, or according to the Pediatric Oncology
Group (POG) 8346 protocol,7 which calls for either surgery
or deﬁnitive RT to be delivered in week 12 after initiation
of chemotherapy with cyclophosphamide and doxorubicin
(Table 1). The most common scheme used was the one based
on the SEOP protocol. Cycles of the SEOP protocol included
six induction cycles of vincristine (1.5mg/m2, day 1), dox-
orubicin (20mg/m2, days 1–3; alternating with actinomycin
D 0.5mg/m2 before 2001), ifosfamide (2 g/m2 before 2001
and 3g/m2 after 2001, days 1–3) and etoposide (150mg/m2,
days 1–3). All patients received consolidation chemotherapy.
The most common scheme used was vincristine (1.5mg/m2)
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Table 2 – Radiation therapy characteristics.
Characteristic No. of patients (%)
RT
Deﬁnitive 22 (61)
Postoperative 13 (36)
Preoperative 1 (3)
RT type
Two-dimensional 21 (58)
Three-dimensional 15 (42)
RT dose (Gy)
≤50 17 (47)
>50 19 (53)
Fractionation (cGy)
180 q.d. 24 (67)reports of practical oncology and
ay 1, actinomycin (0.75mg/m2) days 1–2 and cyclophos-
hamide (1500mg/m2) day 1, for a total of eight cycles. Since
995, end-intensiﬁcation with megatherapy using high-dose
hemotherapy (busulfan and melphalan) and stem cell res-
ue was delivered in 14 patients (38.9%) according to our
one marrow (BM) transplant protocol. Indications for dose-
ntensive/myeloablative therapy against ES were: (1) patients
ith non metastatic unresectable tumors; (2) patients with
ung/pleural metastasis, if they had disappeared at week 18
fter neoadjuvant chemotherapy; (3) patients with multicen-
ric tumor or with BM metastasis if there had been a response
50% at week 18 after neoadjuvant chemotherapy.
.5. Radiation therapy
peciﬁc characteristics of RT treatment, including dose,
ractionation, and technique, were determined by review-
ng radiation treatment charts and ﬁlms. Patients treated
efore 2000 (53% of cases) had treatment planned with two-
imensional non conformal techniques, in which initial ﬁelds
ncompassed the primary tumor plus a 2 cm margin. Patients
reated in 2000 or later were treated with three-dimensional
onformal techniques targeting the primary lesion at diagno-
is plus a 4 cm craneocaudal margin and 2 cm in the other
xis, except in cases where this would result in overdosing of
n adjacent critical structure (such us epiphysis, spinal cord
r ovary).
Deﬁnitive radiation therapy was delivered in the following
ases: unresectable location or not enough tumor regression
o allow the surgery. Postoperative RT was delivered if the his-
ological tumor response was poor (>10% viable tumor cells)
nd if the margins were positive after surgery. According to
he SEOP protocol, postoperative RT was initiated as soon as
ossible if there was a residual tumor after surgery or concur-
ently with the second cycle of the adjuvant chemotherapy
approximately three weeks after surgery) if there was a com-
lete resection. Preoperative radiation therapy was indicated
n emergency cases (such us medullar compression) or tumor
rogression after induction chemotherapy. In our series, there
as only one case that received a preoperative radiotherapy.
eﬁnitive RT was initiated after eight weeks of the bone mar-
ow transplant when indicated. High-risk patients received
ore aggressive systemic therapy, but RT techniques were not
odiﬁed. Twenty-two (61.1%) patients were treated with pri-
ary RT. In general, deﬁnitive RT tumor volumes have been
hrinking with the availability of superior imaging in today’s
ra. The RT consisted of radiation to the entire bone or bones
ontaining the original lesion, followed by a boost to the lesion
ith a 2–4 cm margin.
Dose was prescribed to cover at least 95% of the planning
arget volume. PreTighter medial margins were occasionally
sed in the pelvis to spare the bladder and bowel. All RTs were
elivered using megavoltage technology, either 60Co (21% of
atients, most of them before 1989) or 6–18MV photons. The
ose of RT for all patients ranged from 43.2Gy to 64.8Gy. It was
erformed on a singular basis. Fraction size was 1.8–2Gy. The
edian dose was 55Gy (range 43.2–64.8Gy) for patients who
eceived deﬁnitive RT and 45Gy (range 30–55.8Gy) for patients
ho received pre/postoperative RT. Local failure in deﬁnitive200 q.d. 12 (33)
Abbreviations. RT= radiotherapy; q.d. = once daily.
RT cases was deﬁned as growth of the residual abnormality or
recurrence of the lesion after a complete resolution on imag-
ing and clinically. Sites of distant metastases (lung and bone)
were also routinely irradiated. Additional details regarding RT
treatment characteristics are outlined in Table 2.
3.6. Outcome measurement and statistics
All statistical computations were performed using SPSS (ver-
sion 17.0) statistical software. The Kaplan–Meier product-limit
method provided estimates of the following end points: over-
all survival (OS), disease free survival (DFS), local control (LC),
and freedom from distant metastasis (FFDM).19 The start of
treatment was deﬁned as either the start of radiation or the
date of surgery, whichever was earlier. Survival times were
calculated as the time from the start of treatment to either
the event or the date of last follow-up. The event for the end
points of interest was deﬁned as follows: OS equals death
from any cause, DFS equals failure (local or distant), LC equals
failure at the local site, and FFDM equals distant metastasis.
The OS, DFS, LC, and FFDM rates were calculated based on
all incidents until censor. The log-rank test statistic allowed
detection of statistically signiﬁcant differences between strata
of selected explanatory variables. Variables included in anuni-
variate analyses were age (≤10 years versus >10 years), tumor
volume (<150 cm3 versus ≥150 cm3), resectability (resectable
versus unresectable), dose intensive/myeloablative therapy
(yes versus no), surgery (yes versus no), radiation therapy
(pre/postoperative versus deﬁnitive), phosphatase alkaline
(≤279 IU/l versus >279 IU/l), year of treatment (<1995 versus
≥1995), lag time between symptom onset and diagnosis (<3
months versus ≥3 months), local recurrence (yes versus no)
and distant recurrence (yes versus no).
4. Results
4.1. PatientsBetween 1981 and 2008, a total of 36 children patients (deﬁned
as <18 years) were treated with radiation therapy for ES at
our Institution. The median age at diagnosis was 10 years
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Table 3 – Patient characteristics.
Characteristic Deﬁnitive
radiotherapy
(N=22)
Pre/postoperative
radiotherapy
(N=14)
Gender
Male 17 (77.3%) 4 (28.6%)
Female 5 (22.7%) 10 (71.4%)
Median age (range), y 9 (3–17) 10 (2–14)
Clinical presentation
Swelling 5 (22.7%) 4 (28.6%)
Functional disability 8 (36.5%) 0
Pain 3 (13.6%) 3 (21.4%)
Neurological symptoms 3 (13.6%) 1 (7.1%)
Others 3 (13.6%) 6 (42.9%)
Primary tumor site
Upper extremity 0 1 (7.1%)
Lower extremity 0 5 (35.7%)
Head 1 (4.5%) 3 (21.5%)
Spine 6 (27.3%) 0
Ribs 0 3 (21.5%)
Scapula 1 (4.5%) 1 (7.1%)
Pelvis 14 (63.7%) 1 (7.1%)
Tumor size (cm)
≤ 8 10 (45.5%) 7
> 8 12 (54.5%) 7
Fig. 1 – Five-year local control. Solid line, deﬁnitive
patients was 66% (95% CI: 49–82%) and 48% (95% CI: 31–66%),
respectively. Two-year DFS rates for patients treated with
deﬁnitive or pre/postoperative RT were 61% and 70%, respec-
tively (P=0.474). Distant metastases (14 cases, 38.9%) were theMetastasis at diagnosis
Lung 5 (22.7%) 0
Bone 1 (4.5%) 1 (7.1%)
Without metastasis 16 (72.3%) 13 (92.9%)
(range 2–17 years). Nineteen patients were 2–10 years old and
17 patients were older than 10 years. All were treated with
chemotherapy (55.5%, according to the SEOP protocol for ES),
13 underwent surgery before RT and 1 after RT. All patients had
pathologically conﬁrmed ES. Diagnosis was based on biopsy
specimens, tumor morphologic characteristics, and immuno-
histochemical analysis. Staging was based on the patient’s
history, physical examination, chest X-ray, X-ray of the pri-
mary tumor, blood chemistry test results, complete blood
count, computed tomography or magnetic resonance imaging
of the primary tumor, and computed tomography of the chest,
when available. Patients who presented with metastatic dis-
ease at the time of diagnosis were not excluded. We divided
patients into two treatment groups: those treated with deﬁni-
tive radiotherapy and those who received pre/postoperative
radiotherapy. There were 22 patients in the ﬁrst group and 14
patients in the other one. The most common site of primary
tumor was the pelvis, followed by the spine. More than half
thepatientshad tumors larger than8 cm. Soft-tissue invasions
were common (Table 3).
4.2. Treatment outcome
Median follow-up was 105 months (range 10–222 months)
for living patients. There were 5 local relapses (four located
in the pelvis and one in the orbit); 4 occurred within the
ﬁrst 2 years. Two out of the ﬁve local recurrences were suc-
cessfully treated with salvage surgery. At 2 and 5 years, the
overall LC rate was 88% for all patients. Comparing patient
treated with deﬁnitive or pre/postoperative RT, there was no
signiﬁcant difference (P=0.972). Five-year LC rates were 91%radiotherapy, N=22; dotted line, pre/postoperative
radiotherapy, N=14.
and 86%, respectively (Fig. 1). There were 22 deaths (one due
to sepsis postchemotherapy, four due to progression of the
disease during the oncologic treatment [two of them were
initially stage IV], three due to local progression [all of them
located at the pelvis] and fourteen due to metastatic relapses
in the follow up); 11 occurred within the ﬁrst 2 years and 19
out of 22 occurred within 5 years. The 2 and 5-year OS rate
for all patients was 68% (95% CI: 52–83%) and 44% (95% CI:
28–61%), respectively. There was no signiﬁcant overall sur-
vival difference between patients treated with deﬁnitive or
pre/postoperative RT (P=0.395). Two-year OS rates were 60%
and 78%, respectively (Fig. 2). The 2 and 5-year DFS rate for allFig. 2 – Five-year overall survival. Solid line, deﬁnitive
radiotherapy, N=22; dotted line, pre/postoperative
radiotherapy, N=14.
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Table 4 – Results of univariate analysis showing risk
factors affecting overall mortality.
Hazard
ratio
Conﬁdence
interval (95%)
P
Age (years)
≤10 1.00
>10 1.24 (0.54–2.87) 0.609
Tumor volume (cm3)
<150 1.00
≥150 1.24 (0.50–3.07) 0.640
Resectability
Resectable 1.00
Unresectable 1.27 (0.49–3.25) 0.624
Dose intensive/myeloablative therapy
Yes 1.00 0.424
No 1.45 (0.59–3.57)
Surgery
Yes 1.00
No 1.33 (0.57–3.08) 0.508
Radiation therapy
Pre/postoperative 1.00
Deﬁnitive 1.45 (0.61–3.47) 0.403
Phosphatase alkaline (IU/l)
>279 1.00
≤279 4.43 (1.25–15.75) 0.021
Year of treatment
≥1995 1.00
<1995 1.48 (0.63–3.48) 0.364
Lag time between symptom onset and diagnosis (months)
≥3 1.00
<3 1.65 (0.71–3.84) 0.246
Local recurrence
No 1.00
Yes 3.76 (1.35–10.46) 0.011reports of practical oncology and
rimary mode of disease recurrence. At 2 and 5 years, the
verall FFDM rate was 73% (95% CI: 57–89%) and 53% (95% CI:
5–72%), respectively, for all patients. Although the rate was
reater in patients treated with pre/postoperative RT, the dif-
erence is not statistically signiﬁcant. Two-year FFDM rates
ere 75% in the patients treated with pre/postoperative RT
nd 64% in the patients treated with deﬁnitive RT (P=0.199).
here were 14 distant relapses; 9 occurred within the ﬁrst 2
ears and 13 out of 14 occurred within 5 years.
Lungs were the most common site of distant metastasis (6
ases), followed by the bone (one case). Six out of 7 (6male, one
emale) metastatic patients had the primary tumor located at
hepelvis andwere treatedwithdeﬁnitiveRTafter noevidence
f metastatic disease was found after induction chemother-
py. Two of them received pulmonary RT. Four were treated
ith two-dimensional technique and before 1998. Only one
ut of 6 patients had no tumor recurrence (last follow up: 19
ears after diagnosis). The other ﬁve plus the one that was
reated with pre/postoperative RT died after developing dis-
ant metastasis (most of them 2 years after treatment).
In the present study, we compared OS stratiﬁed to several
actors (Table 4). Phosphatase alkaline was evaluated at diag-
osis in 70% of patients. In our laboratory, the lower normal
eference limit for phosphatase alkaline is 280 IU/l. We divided
hese patients in two groups: one >279 IU/l (84%) and the
ther one ≤279 IU/l (16%). Phosphatase alkaline ≤279 IU/l at
iagnosis and local and distant recurrences were signiﬁcantly
redictive of worse prognosis (P=0.021; P=0.011; P=0.007,
espectively).We also analyzed the patients’ outcomedepend-
ng on if they were treated before or after the SEOP protocol,
hich was initiated in 1995. Fifteen were treated before
995 while 21 were treated after 1995. Three patients had
etastatic disease at diagnosis in the group treated before
995 and 4 in the other group. Forty percent (6 cases) of
atients were treated with deﬁnitive RT before 1995 and 76.2%
16 cases) in the other group. Two-year OS rates for all patients
ere 60% before 1995 and 74% after 1995 (P=0.356) and two-
ear LC rates were 80% and 95%, respectively (P=0.423).
. Discussion
he Ewing family of tumors is a group of highly aggressive
eoplasms that occur predominantly in children and young
dults.20 Multicenter trials have shown the importance of both
ggressive local treatment and adjuvant systemic chemother-
py. The 5-year outcome following multidisciplinary therapy
eveals local control rates of 74–93%.8,21–24 Our 2 and 5-year
C rate of 88% is consistent with the literature. With deﬁni-
ive irradiation, the 5-year local regional control rate was 91%.
hese rates conﬁrm the value of RT for local control. Local
ontrol rates were high in both arms: the arm of patients
reated with deﬁnitive RT and the arm of patients treated
ith adjuvant RT. It also needs to be reminded that patients
reated with deﬁnitive RT of our series were those with unre-
ectable locations, most of them in the pelvis. In patients with
ocalized disease at diagnosis, established predictors for poor
urvival include a large primary tumor and primary tumor
f the pelvis.25 Studies report outcomes comparing surgery,
T, or the combination thereof, with little explanation as toDistant recurrence
No 1.00
Yes 3.66 (1.43–9.38) 0.007
selection factors, which dictate local therapy decisions. There
never will be, nor should there be a randomized study compar-
ing irradiation versus surgery, because of the inherent bias in
the selection of one therapy over another. Resectable lesions
are usually small, peripheral in location, and follow a good
response to induction chemotherapy. Irradiated lesions are
often large, central in location, and follow a poor response
to induction chemotherapy. These factors make proper ran-
domization impossible. The most commonly employed local
management currently is risk adapted, using local therapy
guidelines. Using such an approach, the outcome and func-
tionhave continuously improved. Radiation therapy standards
andaccuracyhave improvedwithquality assuranceprograms.
While external beam radiation will continue to be a widely
used method, innovative approaches using intraoperative RT
or other targeted approaches may also be useful. Technical
advances using highly conformal three-dimensional tech-
niques, such as intensity modulated RT and proton therapy
in selected cases, will further optimize radiation treatment.
Local and distant recurrences were signiﬁcantly predictive
statistically of worse prognosis. In our study, overall survival
d rad
r108 reports of practical oncology an
and disease free survival rates were almost equal, which
suggests the worse prognostic of patients with either local
or distant metastasis. The location of the local recurrences
observed (such as the pelvis) makes a surgical approach dif-
ﬁcult, which has a strong inﬂuence on the outcome. On the
other hand, we also found that low phosphatase alkaline level
at diagnosis was a worse prognostic factor. Since alkaline
phosphatase concentrations rise during active bone forma-
tion in growth, infants and children normally have levels
that may be three times as high as those of adults. Some
studies26,27 have shown that age is a prognostic factor for
Ewing’s Sarcoma, with better prognosis for younger patients.
We speculate that patients that have lowphosphatase alkaline
level at diagnosis are those that are older and, therefore, they
could be associated with a worse prognosis. Nevertheless, we
consider that this result should be conﬁrmed in studies with
more number of patients.
The U.S. Surveillance Epidemiology and End Results
database published survival data for Ewing family tumors
for patients aged 0–19 years. Five-year OS rates were 42% in
1975–1984 to 58% in 1985–1994 and 60% in 1996–2004. Treat-
ments of our study were delivered from 1981 to 2008 with 2
and 5-year OS rate for all patients of 68% and 44%, respec-
tively. We wanted to assess if the use of modern protocol, such
as the SEOPprotocol andmodern radiotherapywith conformal
three-dimensional techniques alongwith optimal chemother-
apy, had an inﬂuence on patients’ outcome. Although we did
not ﬁnd statistically signiﬁcant survival differences between
patients treated before or after 1995, we observed a trend of
better results in the modern era (two-year OS rates 60% versus
74% and LC rates 80% versus 95%, respectively).
As any study that utilizes an observational database, ours
has several limitations. These include: (1) heterogeneity of sys-
temic treatments, (2) small number of patients treated over
a period of 30 years during which time advances in imag-
ing have occurred and (3) RT was given at different times
during chemotherapy, using different techniques. Despite all
these limitations, the results in terms of local control were
excellent.
6. Conclusions
We have reported the results of multiagent systemic therapy
and RT for patients with ES treated at a single institution dur-
ing the last decades. Within this group of patients, the LC
rates were high in patients treated with deﬁnitive radiation
and pre/postoperative RT. The ﬁndings of this retrospective
review highlight the important role of RT in the multidis-
ciplinary management of ES of bone in pediatric patients,
typically involving sites difﬁcult to approach with surgical
resection. Radiotherapy is also a good option for consolidat-
ing the surgical treatment of such patients with high risk
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